Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
14.70
+0.71 (5.08%)
At close: Jun 6, 2025, 4:00 PM
14.41
-0.29 (-1.97%)
After-hours: Jun 6, 2025, 4:32 PM EDT
Dyne Therapeutics Employees
Dyne Therapeutics had 191 employees as of December 31, 2024. The number of employees increased by 50 or 35.46% compared to the previous year.
Employees
191
Change (1Y)
50
Growth (1Y)
35.46%
Revenue / Employee
n/a
Profits / Employee
-$1,922,147
Market Cap
1.67B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 191 | 50 | 35.46% |
Dec 31, 2023 | 141 | 22 | 18.49% |
Dec 31, 2022 | 119 | 26 | 27.96% |
Dec 31, 2021 | 93 | 46 | 97.87% |
Dec 31, 2020 | 47 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
DYN News
- 2 days ago - Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress - GlobeNewsWire
- 4 weeks ago - Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 6 weeks ago - Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy - GlobeNewsWire
- 7 weeks ago - Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments - GlobeNewsWire
- 7 weeks ago - Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer - GlobeNewsWire
- 2 months ago - Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months - GlobeNewsWire